Bausch + Lomb and Novaliq have completed enrollment in a phase 3 study evaluating NOV03 for the treatment of signs and symptoms of dry eye disease associated with meibomian gland dysfunction, according to a press release.
The study is the first of two phase 3 studies evaluating NOV03 (perfluorohexyloctane) and enrolled 599 participants.
In addition, the companies announced the publication of results from the phase 2 SEECASE clinical study evaluating NOV03. The therapy reached its primary efficacy endpoint of statistically significant improvement of total corneal fluorescein staining over
Uncategorized